Eylea (aflibercept) is Regeneron’s anti-VEGF injection for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion. It comes in two strengths that are priced and billed as separate products: Eylea 2 mg and the higher-dose Eylea HD at 8 mg.

The big change for 2026 is competition. Six aflibercept biosimilars are FDA approved, two are actually on the market, and more have launch dates on the calendar through January 2027. That is starting to move published prices, though not always in the direction you would expect. This guide separates the drug cost from the injection cost, shows the arithmetic behind each figure, and lays out where the biosimilars actually sit. Everything below was researched September 3, 2026.

What Does Eylea Cost Without Insurance?

Medicare pays for Eylea 2 mg under HCPCS J0178 with a billing unit of 1 mg, so a standard dose is 2 billing units. The Part B payment limit effective July 1 through September 30, 2026 is $743.605 per milligram, which is 2 x $743.605 = $1,487.21 per dose. Eylea HD uses J0177 at $298.683 per milligram, and an 8 mg dose is 8 x $298.683 = $2,389.46.

Eylea cost itemLowAverageHigh
Eylea 2 mg, drug only, one injection$1,487.21 (CMS Part B limit)$1,918.34 (CMS 2024 per claim)$2,038.61 (published list price)
Eylea HD 8 mg, drug only, one injection$2,389.46 (CMS Part B limit)$3,141.51 (CMS 2024 per claim)$3,141.51
Pavblu (aflibercept biosimilar) 2 mg, CMS Part B limit$1,606.51$1,606.51$1,606.51
Yesafili (aflibercept biosimilar) 2 mg, launch list price$1,445.00$1,445.00$1,445.00
Compounded bevacizumab, 1.25 mg dose, Medicare drug rate$9.35$9.36$9.36
Injection fee only, CPT 67028, Medicare rates$114.23 (physician office)$114.23$337.46 (hospital outpatient)
Eylea 2 mg plus office injection fee, one eye$1,601.44$2,032.57$2,152.84
One year of treatment, CMS 2024 Medicare average per beneficiary$8,065.22 (Eylea)$8,065.22$9,971.70 (Eylea HD)

For a reality check, CMS’s Medicare Part B spending file for 2024 records $2.37 billion in Eylea spending across 1,233,027 claims and 293,280 beneficiaries, which is $1,918.34 per claim and $8,065.22 per beneficiary for the year. Eylea HD accounted for $665.8 million across 211,930 claims and 66,767 beneficiaries, or $3,141.51 per claim and $9,971.70 per beneficiary. Some claims cover both eyes at one visit, which pushes the per-claim averages above a single-eye dose.

The injection is billed separately

The procedure is CPT 67028, intravitreal injection of a pharmacologic agent. CMS’s July 2026 relative value file assigns it 3.42 total non-facility relative value units. Multiplied by the 2026 conversion factor of $33.4009, that is $114.23 in a physician office.

A hospital outpatient department is priced differently. July 2026 OPPS Addendum B pays the facility $337.46 for 67028 under APC 5694, and the physician then bills a separate professional fee at the facility rate of roughly $75.49. Same procedure, roughly triple the cost, purely because of the building.

What Drives the Price

Biosimilars, and the gap between approved and available. FDA has approved six aflibercept biosimilars: Yesafili (Biocon) and Opuviz (Samsung Bioepis) in May 2024, Ahzantive (Formycon) in June 2024, Pavblu (Amgen) and Enzeevu (Sandoz) in August 2024, and Eydenzelt (Celltrion) in October 2025. Only two have launched. Pavblu went first in November 2024, and Biocon launched Yesafili on August 3, 2026 at a wholesale acquisition cost of $1,445 against Eylea’s $2,038.61. Enzeevu is expected in the fourth quarter of 2026, Eydenzelt in late December 2026, and Opuviz in January 2027.

A counterintuitive quirk in Medicare’s file. Pavblu has its own Part B code, Q5147, and its July 2026 payment limit is $803.255 per milligram, which is $1,606.51 for a 2 mg dose. That is higher than the brand’s $1,487.21. This is not a typo and it held across two quarters (Pavblu was $821.396 per milligram in the April 2026 file, Eylea was $731.885). Medicare’s allowances are built from reported average sales price net of discounts, and Eylea’s has fallen fast as Regeneron competes. On list price the biosimilars are clearly cheaper; on Medicare’s ASP-based allowance, right now, they are not.

Quarterly resets. Every J-code and Q-code figure on this page comes from the file covering July 1 through September 30, 2026, built on first-quarter 2026 sales data. The next reset takes effect October 1, 2026 and will change all of them.

Which strength you are on. Eylea HD costs more per dose but is given less often. Comparing per-dose prices between the two is the wrong comparison; the annual per-beneficiary figures above are the right one.

Setting and bilateral treatment. Physician office versus hospital outpatient department is a roughly threefold swing on the procedure fee, and everything here is per eye.

Cash Price vs. Insurance

Under traditional Medicare Part B the beneficiary coinsurance on J0178 is 20%, which is about $297.44 on a $1,487.21 allowed amount, and a Medigap or retiree plan usually absorbs it.

With commercial insurance, Regeneron’s EYLEA4U Commercial Copay Card can bring your cost to as little as $0 per treatment. The program covers up to $20,000 per rolling year toward product copay, coinsurance, and deductibles, plus a separate $1,000 per year toward administration costs. Regeneron states there is no annual income verification and no limit on program participation, but the card is void for anyone covered by Medicare, Medicaid, VA, DoD, or TRICARE, and Massachusetts and Rhode Island residents are excluded from the administration benefit.

If you are uninsured or underinsured, Regeneron’s separate Patient Assistance Program may provide Eylea at no cost. Eligibility runs on total annual household income, enrollment lasts up to 12 months, and you have to reapply each year. The number is 1-855-EYLEA4U, option 4.

For an uninsured patient, that free-drug program is almost always the better play than negotiating a cash price, because the drug is the expensive half of the bill and the manufacturer can zero it out entirely.

The Bevacizumab Question

The single most useful cost fact on this page is that the drug retina specialists use most often in the U.S. is not Eylea. It is bevacizumab, a cancer drug used off label in the eye for about twenty years, split by compounding pharmacies into small intravitreal doses.

The price difference is not subtle. Medicare’s July 2026 Part B limit for bevacizumab is $74.823 per 10 mg under J9035, and the hospital outpatient code for the ophthalmic dose, C9257, pays $1.871 per 0.25 mg. Either way, the drug ingredient in a 1.25 mg intravitreal dose is about $9.35. Even after a compounding pharmacy’s preparation and shipping costs, this is one or two orders of magnitude below every branded option in the table above.

That landscape changed in July 2026. On July 24, 2026, the FDA approved Lytenava (bevacizumab-vikg) from Outlook Therapeutics, the first and only ophthalmic formulation of bevacizumab approved in the United States, for wet AMD. Outlook expects to make it available before the end of 2026 and has not published a U.S. price.

None of this is a recommendation. Which anti-VEGF drug belongs in your eye is a clinical decision that depends on your diagnosis, your response to treatment, and your retina specialist’s judgment. But asking your doctor what each option would cost you, and whether bevacizumab is appropriate for your condition, is a fair and normal question that a lot of self-pay patients never think to ask.

How to Pay Less

  1. Apply to the EYLEA4U Patient Assistance Program before your first bill. If you are uninsured, underinsured, or your plan does not cover Eylea, this is the highest-value step available and it can take the drug cost to zero. Call 1-855-EYLEA4U (1-855-395-3248), option 4.

  2. Ask which aflibercept product the practice stocks. Two biosimilars are on the market and three more arrive by January 2027. Yesafili’s list price is $1,445 against Eylea’s $2,038.61, a difference of nearly $600 a dose. Practices stock what their purchasing contract favors, so the answer may be no, but the question is free.

  3. Choose a physician office over a hospital outpatient department. Medicare’s own rates move from $114.23 to $337.46 for the identical injection code. If a hospital is your only option, our guide to hospital price transparency shows how to pull its posted cash rate first, and the charity care checker tells you whether that hospital has a financial assistance policy you might qualify for.

  4. Get the quote broken into three numbers and negotiate the two you can move. Drug, injection (CPT 67028), and office visit. Our fair price checker helps you benchmark the procedure and visit portions, and our guide to negotiating medical bills has the script for asking a practice for its self-pay rate in writing. If a hospital did the billing, hospital charity care can erase the facility half.

  5. Request an itemized bill every single time. These claims carry a drug code and a procedure code and sometimes an office visit code, and unit errors on a drug billed in 1 mg increments are easy to make and expensive to miss. Our guide to reading an itemized hospital bill covers what to look for.

  6. Apply to independent charitable foundations if you have Medicare. Regeneron’s own page names Good Days, the HealthWell Foundation, and the PAN Foundation. Their macular degeneration and diabetic eye disease funds open and close during the year, so apply the day one opens.

  7. Price the care around the injections separately. A free or sliding-scale clinic can often handle routine monitoring, an eye exam has its own cash price, and if diabetes is driving your retinal disease then metformin and a continuous glucose monitor are worth pricing on their own.

Bottom Line

Budget about $1,487 to $2,039 for the Eylea 2 mg vial and $114 to $337 for the injection, which puts one treatment in one eye at roughly $1,600 to $2,380 as of September 2026. Eylea HD runs about $2,389 per dose at Medicare’s allowance but is given less often. CMS’s real 2024 data puts annual Medicare drug spending at $8,065.22 per Eylea patient and $9,971.70 per Eylea HD patient.

Watch two things. Medicare’s Part B allowances for every code here reset on October 1, 2026, so re-check the figures after that date. And the aflibercept biosimilar market is mid-launch, with three more products expected between the fourth quarter of 2026 and January 2027, which should keep pushing list prices down. If you are budgeting eye care more broadly, Vabysmo is the other major retina injectable, and cataract surgery and glaucoma drops have entirely separate pricing.